Cost-effectiveness analysis has to consider all available evidence when informing inputs.

Dear Dr. Ellis,We read with interest the recent cost-effectiveness analysis (CEA) published by Ruiz-Aragon et al., 2020,1 concluding: “QIVc [Flucelvax] offers a cost-effective alternative to QIVe [...